Zenith Healthcare board approves merger of Achyut Healthcare into itself

Acquisition announcedScheme filed with the NCLTStrategic Transactions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+8.9%Reaction day

₹3.05

prior close

₹3.11

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+8.2% vs market

Pharmaceuticals peers, median of 165sector+0.0%+8.8% vs sector

On the reaction day the stock moved 8.2 pts more than Nifty Microcap 250 and 8.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.5

10m

+5.8

15m

+3.9

30m

+3.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+8.9+0.6+8.2+0.0+8.8

Next day

+9.2+0.2+9.0+0.0+9.2

+7.2-0.9+8.1-1.1+8.3

+12.5-0.3+12.8-0.5+13.0

+14.8+0.0+14.7-0.4+15.1

+10.8-1.1+12.0-1.7+12.5

+6.9-1.4+8.3-2.6+9.5

15d

+4.6+2.7+1.9-1.2+5.8

+1.0+3.6-2.6-0.5+1.4

+7.2+2.0+5.2-0.6+7.8

+3.0+1.1+1.9-2.3+5.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zenith Healthcare board approved merging group company Achyut Healthcare into itself under Companies Act Sections 230-232. Exchange ratio fixed at 119 Zenith shares per 50 Achyut shares; no cash involved. Achyut is larger with assets of about Rs 38 crore and turnover of Rs 12 crore in FY26, versus Zenith assets of about Rs 11 crore. Post-merger, Zenith promoter holding will rise from 28.74% to 45.80% while public stake falls from 71.26% to 54.20%. Subject to NCLT, BSE no-objection and shareholder and creditor approvals.

Likely market impact

Group restructuring - existing public shareholders face significant dilution. Subject to NCLT and shareholder approvals before becoming effective.